Evolving molecularly targeted therapies for advanced-stage thyroid cancers.

Area of Science:

• Oncology
• Molecular Medicine
• Pharmacology

Background:

• Advanced thyroid cancers, including medullary thyroid cancer (MTC), differentiated thyroid cancer (DTC), and anaplastic thyroid cancer (ATC), present significant therapeutic challenges.
• Recent advancements in understanding disease-specific molecular targets have led to targeted therapies for MTC and radioactive iodine-refractory DTC.

Purpose of the Study:

• To summarize progress in molecular medicine for advanced-stage thyroid cancers.
• To analyze the impact of new therapies on patient care and identify future research directions.

Main Methods:

• Review of recent clinical trial data and regulatory approvals for thyroid cancer therapies.
• Analysis of molecular pathways and their therapeutic relevance in different thyroid cancer histotypes.

Main Results:

• Vandetanib and cabozantinib approved for MTC; sorafenib and lenvatinib approved for refractory DTC.
• Multimodality therapy may improve survival in early-stage anaplastic thyroid cancer (ATC), but salvage therapy benefits are uncertain.
• Numerous phase II and III clinical trials are ongoing for novel therapeutic strategies in DTC and ATC.

Conclusions:

• Targeted therapies represent a significant advancement in treating specific thyroid cancer subtypes.
• Further research is crucial to elucidate the effects of these therapies on overall survival and quality of life.
• Continued exploration of molecular pathways and their interactions is essential for developing personalized and effective treatments for all thyroid cancer types.